Literature DB >> 3907235

Glycemic control with an artificial pancreas improves insulin responses to both oral and glucose in nonobese noninsulin-dependent diabetic subjects.

D Giugliano, P Di Pinto, A Ceriello, G Paolisso, F Saccomanno, R Torella, F D'Onofrio.   

Abstract

Insulin secretory responses to both oral and intravenous glucose were investigated in 12 nonobese noninsulin-dependent diabetic subjects before and after strict metabolic control of blood glucose levels without weight loss. Glycemic control was achieved by applying an artificial pancreas to all diabetics for 2 or 3 days, which led to restoration of normal fasting blood glucose levels and to significant reduction of fasting plasma insulin (p less than 0.01) and C-peptide (p less than 0.05) levels. Initially, the insulin response to oral glucose was weak and delayed, but increased significantly after treatment (p less than 0.01), although none of the diabetic subjects achieved completely normal glucose tolerance. The i.v. glucose tolerance test (0.33 g/kg) revealed that all diabetics lacked acute insulin response in the basal state with low glucose disappearance rates (0.37 +/- 0.07 %/min). After 48h of normoglycemia, these figures did not change significantly, although the insulinogenic index (insulin area/glucose area) was significantly increased (p less than 0.05). A marked increase in both phases of insulin secretion was evident when a larger intravenous glucose pulse (0.66 g/kg) was used in some diabetics in order to raise the blood glucose concentrations of the post-treatment test to those of the pre-treatment test. In absolute terms, the insulin responses of the post-treatment tests were not significantly different from those of sex-, age- and weight-matched control subjects, but were significantly lower if related to the corresponding plasma glucose responses (insulinogenic index lower than that of controls). These studies in nonobese noninsulin-dependent diabetic subjects indicate that glycemic control with an artificial pancreas improves insulin response to glucose, suggesting that chronic hyperglycemia may stress the impaired B-cell secretory capacity of diabetes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907235     DOI: 10.1007/bf02590771

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  26 in total

1.  Effects of streptozotocin-induced diabetes on insulin binding, glucose transport, and intracellular glucose metabolism in isolated rat adipocytes.

Authors:  M Kobayashi; J M Olefsky
Journal:  Diabetes       Date:  1979-02       Impact factor: 9.461

2.  Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for imparied glucose potentiation.

Authors:  J B Halter; R J Graf; D Porte
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

3.  Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus.

Authors:  P J Savage; L J Bennion; E V Flock; M Nagulesparan; D Mott; J Roth; R H Unger; P H Bennett
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

4.  Effect of control of blood glucose on plasma insulin responses to various stimuli in secondary failures to oral hypoglycemic agents and in newly diagnosed, maturity onset, ketosis-resistant diabetics.

Authors:  R Schmeltz; H J Wendorff; J B Field
Journal:  J Clin Endocrinol Metab       Date:  1978-04       Impact factor: 5.958

5.  Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.

Authors:  R C Turner; S T McCarthy; R R Holman; E Harris
Journal:  Br Med J       Date:  1976-05-22

6.  The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia.

Authors:  P Vague; J P Moulin
Journal:  Metabolism       Date:  1982-02       Impact factor: 8.694

7.  Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects.

Authors:  J P Palmer; J W Benson; R M Walter; J W Ensinck
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

8.  Calcitonin, a diabetogenic hormone?

Authors:  N Passariello; D Giugliano; S Sgambato; R Torella; F D'Onofrio
Journal:  J Clin Endocrinol Metab       Date:  1981-08       Impact factor: 5.958

9.  The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.

Authors:  W T Garvey; J M Olefsky; J Griffin; R F Hamman; O G Kolterman
Journal:  Diabetes       Date:  1985-03       Impact factor: 9.461

10.  Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics.

Authors:  H Hidaka; M Nagulesparan; I Klimes; R Clark; H Sasaki; S L Aronoff; B Vasquez; A H Rubenstein; R H Unger
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

View more
  1 in total

1.  Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.

Authors:  R P Robertson; H J Zhang; K L Pyzdrowski; T F Walseth
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.